China Resources Pharmaceutical Group Limited (commonly known as China Resources Pharmaceutical) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Co., Ltd., has received a Notice of Acceptance of Registration (Zhong Shi Xie Zhu [2026] No. MTN455) from the National Association of Financial Market Institutional Investors (NAFMII).

The registration permits the subsidiary to issue medium-term notes in mainland China with a combined principal amount of up to RMB5.00 billion over a two-year validity period. The notes may be launched in multiple tranches during this timeframe.

According to the filing, net proceeds from any issuance will be allocated primarily toward replenishing working capital, repaying interest-bearing debt and other uses permitted under applicable regulations.

The company stated it will release further information should the issuance proceed and advised shareholders and prospective investors to exercise caution when dealing in its securities.